DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.
Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...
Investor's Business Daily on MSN1d
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...
Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli ...
Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual, not just the condition. This simple belief has shaped the way ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback